Treatment of human immunodeficiency virus/acquired immunodeficiency syndrome
Methods of treating a patient with human immunodeficiency virus are disclosed. The method includes a providing intradermal and intravenous doses of a aTh1 composition that can increase the CD4+ cells in a patient that are resistant to HIV. The description includes a method for viral load reduction and a viral purge method. The regimen leads to a spike in the viral load and a then a return to baseline or lower levels of the virus and can lead to reduction and/or elimination of the latent viral reservoirs. Kits configured to provide intradermal doses and intravenous doses according to the regimen are also included.
1 .- 12 . (canceled)
13 . A method of reducing or eliminating HIV-virus from a patient comprising administering escalating intravenous doses of a aTh1 composition to a patient wherein the patient is concurrently treated with HAART.
14 . The method of claim 13 wherein the method further comprises:
increasing the titer of circulating CD4+ Th1 memory cells that are resistant to HIV infection by administering at least one intradermal dose of aTh1 composition to the patient, wherein the patient is infected with HIV; and
expanding and activating the CD4+ Th1 memory cells in the patient by administering at least two doses of the escalating intravenous doses of the aTh1 composition.
15 . The method of claim 13 wherein the method further comprises:
administering at least one dose of a aTh1 composition and at least one dose of one or more HIV-antigens, wherein the titer of circulating CD4+ Th1 memory cells that are resistant to HIV infection are increased in the patient and the viral load is decreased in the patient.
16 . The method of claim 13 wherein the method further comprises:
increasing the titer of circulating CD4+ Th1 memory cells that are resistant to HIV infection by administering at least one intradermal dose of aTh1 composition to the patient, wherein the patient is infected with HIV;
expanding and activating the CD4+ Th1 memory cells in the patient by administering at least two of the escalating intravenous doses of the aTh1 composition; and
administering at least one dose of a aTh1 composition and at least one dose of one or more HIV-antigens, wherein the titer of circulating CD4+ Th1 memory cells that are resistant to HIV infection are increased in the patient and the viral load is decreased in the patient.
17 . The method of claim 13 wherein the HAART is halted and the patient is monitored for CD4+ cells and the viral load.
18 . The method of claim 17 wherein HAART is reinstated if a viral spike is detected in the patient.